

Datasheet: PIP051A

BATCH NUMBER 170628

Description:	RECOMBINANT WEST NILE VIRUS NS1 ANTIGEN
Name:	WEST NILE VIRUS
Format:	Rec. Protein
Product Type:	Recombinant Protein
Quantity:	100 µg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Viral
Product Form	Purified recombinant protein - liquid
Preparation	Recombinant West Nile virus NS1 protein, sequence strain NY99, expressed in 293 human cells
Buffer Solution	Dulbecco's phosphate buffered saline
Preservative Stabilisers	None present
Approx. Protein Concentrations	Approximate protein concentration 0.49 mg/ml

Specificity

Recombinant West Nile Virus NS1 Antigen is a purified preparation of the West Nile virus non-structural protein 1 (NS1).

West Nile Virus (WNV), also known as West Nile Fever, is primarily a mosquito borne virus belonging to the *Flaviviridae* family. In humans the majority of infections are subclinical

with patients experiencing either no or very mild symptoms, however a minority of infections result in severe disease, which may result in fatal encephalitis.

Originating in Africa, WNV was, until recently, not a significant disease of humans. Since the late 1990's the virus has spread widely to other continents and is now an endemic pathogen in the temperate and tropical regions throughout the world. WNV infection is now considered a serious health concern in North America ([Lindsey et al. 2014](#)).

WNV is a zoonotic disease with an avian wildlife reservoir to which passerine and more specifically, corvid species appear to be particularly susceptible with high recorded mortality rates ([Abdelrazec et al. 2014](#)). In addition to the human health concerns and the effect on North American avian species populations ([Wheeler et al. 2011](#)), WNV is also of potential concern in domestic mammals, in particular to equine species where mortality rates are high ([Angenvoort et al. 2013](#)). Fatal cases of West Nile have also been noted in other species including non-human primates, bats and cetaceans. While the primary route of infection is via mosquitoes there is some evidence that infection may also occur from other invertebrate species such as ticks, however further research is required in this area.

Recombinant West Nile virus NS1 antigen is presented in its native folded state complete with post-translational modifications, delivering optimal antigenicity and making it suitable for use in vaccine research and serology-based assays.

Purity >95% by SDS PAGE

Further Reading

1. Wheeler, S.S. *et al.* (2011) Efficacy of three vaccines in protecting Western Scrub-Jays (*Aphelocoma californica*) from experimental infection with West Nile virus: implications for vaccination of Island Scrub-Jays (*Aphelocoma insularis*). [Vector Borne Zoonotic Dis. 11\(8\): 1069–1080.](#)
2. Abdelrazec, A, *et al.* (2014) Transmission dynamics of West Nile virus in mosquitoes and corvids and non-corvids. [J Math Biol. 68\(6\): 1553-82.](#)
3. Lindsey, N.P. *et al.* (2014) West Nile Virus and Other Arboviral Diseases — United States, 2013. [MMWR Morb Mortal Wkly Rep. 63\(24\): 521-6.](#)
4. Angenvoort, J. *et al.* (2013) West Nile viral infection of equids. [Vet Microbiol. 29: 167\(1-2\): 168-80.](#)

Storage Store at -70°C.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee 12 months from date of despatch

Health And Safety Information Material Safety Datasheet documentation #10286 available at: <https://www.bio-rad-antibodies.com/SDS/PIP051A>
10286

Regulatory For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M369556:200529'

Printed on 19 Jan 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)